A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support

Pediatric Blood and Cancer

Volumn 46, Issue 7, 2006, Pages 793-802

  Pradhan, Kamnesh R ^a   Johnson, Cynthia S ^a   Vik, Terry A ^a   Sender, Leonard S ^b   Kreissman, Susan G ^a,c  

^a INDIANA UNIVERSITY   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

High risk neuroblastoma; Induction chemotherapy; Peripheral blood stem cells

Indexed keywords

AMINOTRANSFERASE; CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MYELOABLATIVE AGENT; RETINOIC ACID;

ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER STAGING; CANDIDA TROPICALIS; CATHETER INFECTION; CELLULITIS; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG MEGADOSE; DRUG TOLERABILITY; ESCHERICHIA COLI; FEMALE; FEVER; FOLLOW UP; FUNGEMIA; GASTROINTESTINAL REFLUX; HEARING LOSS; HEMATURIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INFANT; INFECTIOUS COMPLICATION; KAPLAN MEIER METHOD; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MALE; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; NEUTROPENIA; NEUTROPHIL COUNT; ONCOGENE C MYB; OTITIS MEDIA; OVERALL SURVIVAL; PARAINFLUENZA VIRUS; PATIENT SELECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; URINARY TRACT INFECTION; VIRAL RESPIRATORY TRACT INFECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INFANT; LINEAR MODELS; MALE; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 33646588304     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20594     Document Type: Article

References (53)

1. Gurney JG, Davis S, Severson RK, et al. Trends in cancer incidence among children in the U.S. Cancer 1996;78:532-541.
2. Gurney JG, Ross JA, Wall DA, et al. Infant cancer in the US: Histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997;19:428-432.
3. Olshan AF, Bunin GR. Epidemiology of neuroblastoma. Amsterdam: Elseiver Science; 2000. pp 33-39.
4. DeBernardi B, Milanaccio C, Occhi M. Neuroblastoma. In: Sheaves R, editor. Clinical Endocrine oncology. Oxford, United Kingdom: Blackwell Science; 1997. pp 306-311.
5. Bernstein ML, Leclerc JM, Bunin G, et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America, J Clin Oncol 1992;10:323-329.
6. Rosen EM, Cassady JR, Frantz CN, et al. Neuroblastoma; the joint center for radiation therapy/Dana-Farber cancer institute/Children's hospital experience. J Clin Oncol 1984;2:714-732.
7. Finklestein JZ, Klemperer MR, Evans A, et al. Multiagent chemotherapy for children with metastatic neuroblastoma; a report from Children's Cancer Study Group. Med Pediatr Oncol 1979;6:179-188.
8. Bernard JL, Philip T, Zucker JM, et al. Sequential cisplatin/VM26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma; an effective alternating non-cross resistant regimen? J Clin Oncol 1987;5:1952-1959.
9. Green AA, Hayes FA, Rao B. Disease control and toxicity of aggressive 4 drug therapy for children with disseminated neuroblastoma. Proc Am Soc Clin Oncol 1986;5:210.
10. Bernard JL, Hartmann O, Zucker JM, et al. Alternating induction chemotherapy with cyclophosphamide-adriamycin-vincristine (CAD) and high dose cisplatin-etoposide (CVP) for children with metastatic neuroblastoma (NB) over 1 year of age. Preliminary results of the French Cooperative NB87 Protocol. Med Pediatr Oncol 1990;18:385.
11. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-1173.
12. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group Studies. J Clin Oncol 1996;14:2417-2426.
13. Pinkerton R, Philip T, Bouffet E, et al. Autologous bone marrow transplantation in paediatric solid tumours. Clin Haematol 1986;15:187-203.
14. Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 1991;9:1037-1044.
15. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 1998;16:953-965.
16. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multi-variate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999;23:789-795.
17. Kaneko M, Tsuchida Y, Uchino J, et al. Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study group of Japan for treatment of advanced neuroblastoma (see comments). J Pediatr Hematol Oncol 1999;21:190-197.
18. Hartmann O, Berthold F. Treatment of advaced neuroblastoma: The European experience. In: Brodeur GM, editor. Neuroblastoma. Amsterdam: Elseiver Science; 2000. pp 437-452.
19. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991;9:1050-1058.
20. Allen JC, Helson L. High dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 1981;55:749-756.
21. Allen JC, Helson L, Jereb B. Preradiation chemotherapy for newly diagnosed childhood brain tumors. Cancer 1983;52:2001-2006.
22. Longee DC, Freidman HS, et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 1990;72:583-588.
23. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12:2607-2613.
24. Cheung NK, Kushner BH, LaQuaglia M, et al. N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Ped Oncol 2001;36:227-230.
25. Basser RL, To B. Collins JP, et al. Multicycle high-dose chemotherapy and filgastim-mobilized peripheral-blood progenitor cells in women with high-risk Stage II or III breast cancer: Five-year follow-up. J Clin Oncol 1999;17:82-92.
26. Shapiro CL, Ayash L, Webb U, et al. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgastim in advanced breast cancer patients. J Clin Oncol 1997;15:674-683.
27. Honkoop AH, van der Wall E, Feller N, et al. Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. Ann Oncol 1997;8:957-962.
28. Woll PJ, Thatcher N, Lomax L, et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized Phase II trial in small-cell lung cancer patients. J Clin Oncol 2001;19:712-719.
29. Takahashi M, Yoshizawa H, Tanaka H, et al. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer. Bone Marrow Transplant 2000;25:5-11.
30. Bokenmeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221-1227.
31. Bokenmeyer C, Gillis AJM, Pompe K, et al. Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapy. J Clin Oncol 2001;19:3029-3036.
32. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor alter craniospinal radiotherapy: Results of a collaborative study. J Clin Oncol 2001;19:2696-2704.
33. Hawkins DS, Felgenhauer J, Park J, et al. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcoma. Cancer 2002;95:1354-1365.
34. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-1881.
35. August CS, Serota FT, Koch PA, et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogencic or autologous marrow reconstitution. J Clin Oncol 1984;2:609-616.
36. Philip T, Bernard JL, Zucher JM, et al. High dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: An unselected group of stage IV patients over one year of age. J Clin Oncol 1987;5:266-271.
37. Sidell N, Altman A, Haussier MR, et al. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 1983;146:21-30.
38. Reynolds CP, Matthay KK, Grouse VL, et al. Response of neuroblastoma bone marrow metastases to 13-cis-retinoic acid. Proc Am Soc Clin Oncol 1990;9:207.
39. Liang KY, Zeeger SL. Longitudinal data analysis using generalized models. Biometrika 1986;73:13-22.
40. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
41. Fukuda M, Kojima S, et al. Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocytc colony-stimulating factor in childhood neuroblastoma and non-Hodgkin's lymphoma. Br J Haematol 1992;80:327.
42. Takaue Y, Watanabe T, et al. Isolation and storage of peripheral blood hematopoietic stem cells for autotransplantation into children with cancer. Blood 1989;74:1245.
43. Lasky L, Fox S, et al. Collection and use of peripheral blood stem cells in very small children. Bone Marrow Transplant 1991;7:281.
44. Handgretinger R, Klingebiel T, Dopfer R, et al. Peripheral stem cell collection and transplantation in pediatric patients. In: Worthington-White D, editor. Advances in Bone Marrow Purg and Proc. Vol 377. New-York: Wiley-Liss; 1992. pp 615.
45. Kreissman SG, Rackoff WR, Lee MW, et al. High Dose Cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol/Oncol 1997;19:309-312.
46. Rauck AM, Ruymann FB, Klopfenstein K, et al. Mobilization of Peripheral blood stem cells in children using G-CSF after Carboplatin containing myelosuppressive chemotherapy. J Clin Apheresis 1998;13:146-154.
47. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation can return a multiplicity of tumorigenic cells. Blood 1994;84:380-383.
48. Castleberry RP, Cantor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma. A Pediatric Oncology Group Study. J Clin Oncol 1994;12:1616-1620.
49. Adams M, Kirby IJ, et al. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncologic 1989;28:57-60.
50. Freidman HS, Krucher JP, et al. Treatment of children with progressive or recurrent brain minors with carboplatin or iproplatin. A Pediatric Oncology Group randomised phase II study. J Clin Oncol 1992;10:249-256.
51. Castello M, Donfrancesco A, et al. High-dose carboplatin with etoposide (JET regimen) in children with advanced neuroblastoma. Adv Neuroblastoma Res 1991;3:535-542.
52. Kushner BH, Cheung NK, Kramer K, et al. Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 1998;16:3880-3889.
53. Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004;22:4888-4892.